课题基金 / 基金详情

A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION

A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTION
心房传导 3D 体外疾病模型
批准号:
10228624
负责人:
David Terry Curiel
金额:
$106.55万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2023-07-31

项目摘要

项目成果

David Terry Curiel的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
PROJECT SUMMARY Nearly 1 in 10 adults over the age of 65 in the U.S. suffer from atrial fibrillation (AF) leading to approximately $6 billion annually in healthcare costs. Because advanced age is a primary risk factor for developing AF, the overall incidence is expected to rise steadily over the coming decades as our population ages. Current therapeutic interventions have remarkably poor efficacy and/or untoward side effects due in large part to our inability to target the root cause of the disease and provide specificity for the atria and the patient. The central objective of this proposal is to create and validate a robust 3D microphysiological model of abnormal human atrial conduction using induced pluripotent stem cells from the patient. The model will simulate important elements of AF, such as conduction velocity, and develop novel therapeutic strategies that employ adenoviral delivery of gene interference (CRISPRi) that target altered gene regulatory pathways as the source of AF. We will accomplish this objective by completing the following specific aims: 1) characterize the transcriptome, epigenome, and electrophysiology of adult human atrial cardiomyocytes (normal and AF); 2) create a 3D in vitro disease model of human atrial conduction leveraging human iPS cell-derived atrial cardiomyocytes (iPS- aCM) and atrial regulatory gene expression; 3) design and test an adenoviral gene delivery strategy to specifically target atrial (not ventricular or nodal) cardiomyocytes; 4) demonstrate atrial specific adenoviral delivery (SA3) of CRISPRi and gene interference of PITX2 in ex vivo human atrial tissue; and 5) create iPS- aCM and the corresponding in vitro model of atrial conduction from a cohort of normal subjects and patients with AF; characterize drug efficacy and gene delivery in the in vitro models using a panel of existing drugs and our atrial specific adenoviral construct for CRISPR gene interference of PITX2 (SA3). Completing the specific aims will provide a model of human atrial conduction that can be used as a broad platform to understand drug efficacy and safety for diseases such as AF.!
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
Mitigating neutrophil trafficking and cardiotoxicity with DS-IkL in a microphysiological system of a cytokine storm.
在细胞因子风暴的微生理系统中用 DS-IkL 减轻中性粒细胞运输和心脏毒性。
DOI: 10.1039/d2lc01070d
发表时间: 2023
期刊: Lab on a chip
影响因子: 6.1
作者: [Shirure,VenkteshS, Yechikov,Sergey, Shergill,BhupinderS, Dehghani,Tima, Block,AntonV, Sodhi,Harkanwalpreet, Panitch,Alyssa, George,StevenC]
通讯作者: George,StevenC
DOI: 10.1038/s41598-022-24013-y
发表时间: 2022-11-28
期刊: Scientific reports
影响因子: 4.6
作者: []
通讯作者:
A Novel Vector Platform to Actualize T Cell Modification In Vivo
  • 批准号:
    10663022
  • 项目类别:
  • 资助金额:
    $42.76万
  • 财政年份:
    2023
  • 负责人:
    David Terry Curiel
  • 依托单位:
Novel Vector Platform for Gene Therapy
  • 批准号:
    10231536
  • 项目类别:
  • 资助金额:
    $42.23万
  • 财政年份:
    2021
  • 负责人:
    David Terry Curiel
  • 依托单位:
Endothelial-targeted adenovirus for organ-selective gene editing in vivo
  • 批准号:
    10228031
  • 项目类别:
  • 资助金额:
    $74.11万
  • 财政年份:
    2019
  • 负责人:
    David Terry Curiel
  • 依托单位:
Novel Vector Platform for Gene Therapy
  • 批准号:
    10388103
  • 项目类别:
  • 资助金额:
    $37.01万
  • 财政年份:
    2019
  • 负责人:
    David Terry Curiel
  • 依托单位:
海外基金